Created at	Source	Raw Value	Validated value
Oct. 26, 2020, 11:31 p.m.	usa	Incidence of SARS-CoV-2 infection, confirmed by PCR relative to treatment group;Evaluate the number of GLS-1200 topical nasal spray adverse events as assessed by CTCAE v5.0	Incidence of SARS-CoV-2 infection, confirmed by PCR relative to treatment group;Evaluate the number of GLS-1200 topical nasal spray adverse events as assessed by CTCAE v5.0